Josef Parvizi Sells 16,714 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 16,714 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the transaction, the director owned 722,652 shares in the company, valued at approximately $14,648,156.04. This trade represents a 2.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Josef Parvizi also recently made the following trade(s):

• On Thursday, January 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $22.94, for a total transaction of $573,500.00.
• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $21.49, for a total transaction of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total transaction of $506,500.00.

CeriBell Trading Down 0.5%

NASDAQ:CBLL opened at $19.90 on Wednesday. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The firm has a fifty day simple moving average of $21.26 and a 200-day simple moving average of $16.17. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $26.04. The company has a market capitalization of $738.29 million, a P/E ratio of -13.18 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. On average, equities research analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 2025 results beat expectations — EPS of ($0.36) beat the ($0.43) consensus and revenue was $24.78M vs. $23.95M expected, showing topline momentum. Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: FY‑2026 revenue guidance set to $111.0M–$115.0M (midpoint ≈ $113M), which is roughly in line with or slightly above the consensus $112.7M — a modestly constructive signal about growth expectations. CeriBell Press Release / FY2026 Guidance
• Neutral Sentiment: The earnings call transcript and prepared remarks are available for details on product demand, channel dynamics and margin outlook; these may clarify near‑term drivers but did not deliver a clear upside catalyst by themselves. CeriBell Q4 2025 Earnings Call Transcript
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (and has made multiple recent sales), which can be read as a negative signal on near‑term insider conviction despite his remaining large stake. Insider Selling Report
• Negative Sentiment: Profitability and margins remain weak: the business shows a negative net margin (~63%) and negative ROE, keeping valuation metrics and investor confidence constrained despite the beat. Financials Summary

Hedge Funds Weigh In On CeriBell

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after buying an additional 159,698 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of CeriBell during the 2nd quarter valued at about $1,054,000. Emerald Mutual Fund Advisers Trust increased its stake in shares of CeriBell by 58.2% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after purchasing an additional 57,175 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after purchasing an additional 3,502 shares during the period. Finally, F m Investments LLC purchased a new position in CeriBell during the second quarter worth approximately $381,000.

Analysts Set New Price Targets

CBLL has been the topic of several research reports. Canaccord Genuity Group increased their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. decreased their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.